Loading...
•
Mar 31, 2022
Aldeyra Q1 2022 Earnings Report
Aldeyra reported financial results for Q1 2022 and provided corporate highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $16.8 million, or $0.29 per share, for the first quarter of 2022. Cash, cash equivalents, and marketable securities totaled $216.9 million as of March 31, 2022. The company believes existing funds will be sufficient to fund operations through the end of 2023.
Completed enrollment in the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease.
Reported positive top-line data from Phase 2 proof-of-concept trials of ADX-629 and announced new indications.
Initiated Phase 2 Clinical Trials of ADX-629 in Ethanol Toxicity and Chronic Cough.
Dry Eye Disease Clinical Data Presented at 2022 ASCRS Annual Meeting.
Aldeyra
Aldeyra
Forward Guidance
Aldeyra believes that existing cash, cash equivalents, and marketable securities will be sufficient to fund currently projected operating expenses through the end of 2023, including potential NDA submissions; initial commercialization of reproxalap, if approved; and continued development of Aldeyra’s product candidates in ocular and systemic immune-mediated diseases.
Positive Outlook
- Potential New Drug Application submissions
- Initial commercialization of reproxalap, if approved
- Continued development of Aldeyra’s product candidates in ocular diseases
- Continued development of Aldeyra’s product candidates in systemic immune-mediated diseases
- Sufficient funds to support operations through the end of 2023